| News & Announcements | Coverage of Cantharidin (Ycanth) Topical Solution for Commercial Products (Retroactively Effective to 04/01/2024) | | | | | | 8/5/2024 | | | |
| News & Announcements | New Preventive Coverage of 21-valent Pneumococcal Vaccine and Updated Preventive Coverage for Respiratory Syncytial Virus Vaccines for Commercial Members (Retroactively effective to June 7, 2024) | | | | | | 8/28/2024 | | | |
| Notifications | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG) | 08.00.13ai | 7/16/2024 10:00 AM | 10/14/2024 | | | 8/7/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | 8/7/2024 | |
| Notifications | Knee Orthoses | 05.00.47s | 8/13/2024 10:00 AM | 9/13/2024 | | | 8/13/2024 | Medical Necessity Criteria | | |
| Notifications | Osteogenic Stimulators (non-invasive, invasive/semi-invasive, electrical and ultrasound) | 05.00.81a | 8/23/2024 11:00 AM | 9/23/2024 | | | 8/23/2024 | Medical Necessity Criteria | | |
| New Policies | Mirikizumab-mrkz (Omvoh™) for Intravenous Use | 08.02.19 | | 8/12/2024 | | | 8/12/2024 | This is a New Policy. | | |
| New Policies | Secukinumab (Cosentyx®) for Intravenous Use | 08.02.28 | | 8/26/2024 | | | 8/26/2024 | This is a New Policy. | | |
| Updated Policies | Spesolimab--sbzo (Spevigo®) | 08.01.97b | | 8/12/2024 | | | 8/12/2024 | Medical Necessity Criteria | | |
| Updated Policies | Lower Limb Prostheses | 05.00.59o | 7/12/2024 5:00 PM | 8/12/2024 | | | 8/12/2024 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH) | 11.17.06r | | 7/1/2024 | | | 8/12/2024 | Medical Necessity Criteria | | |
| Updated Policies | Daratumumab (Darzalex®), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®) | 08.01.29l | | 8/12/2024 | | | 8/12/2024 | Medical Necessity Criteria;Medical Coding | | |
| Updated Policies | Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris®) for intravenous administration | 08.00.84j | 5/21/2024 10:00 AM | 8/19/2024 | | | 8/19/2024 | Medical Necessity Criteria | | |
| Updated Policies | Trastuzumab (Herceptin®) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) | 08.00.33r | | 8/26/2024 | | | 8/26/2024 | Medical Necessity Criteria;Medical Coding | | |
| Updated Policies | Upper Limb Prostheses | 05.00.72g | | 8/26/2024 | | | 8/26/2024 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Radiofrequency, Cryosurgical and Microwave Ablation of Lung Tumors | 11.00.16i | | 8/26/2024 | | | 8/26/2024 | Medical Necessity Criteria | | |
| Updated Policies | Filgrastim (Neupogen®) and Related Biosimilars, and tbo-filgrastim (Granix®) | 08.01.73f | | 8/26/2024 | | | 8/26/2024 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Reissue Policies | Wheelchair Options and Accessories | 05.00.67t | | 4/1/2024 | 6/12/2024 | | 8/2/2024 | | 8/2/2024 | |
| Reissue Policies | Ublituximab-xiiy (Briumvi®) for intravenous use | 08.02.02a | | 7/1/2023 | 3/6/2024 | | 8/5/2024 | | 8/5/2024 | |
| Reissue Policies | Standing Frames | 05.00.71c | | 3/22/2017 | 8/7/2024 | | 8/7/2024 | | | |
| Reissue Policies | Psychiatric Collaborative Care Management (CoCM) (AmeriHealth) | 00.01.70a | | 1/1/2023 | 8/7/2024 | | 8/7/2024 | | | |
| Reissue Policies | Facility Reporting of Observation Services | 00.01.19e | | 1/4/2021 | 8/7/2024 | | 8/7/2024 | | | |
| Reissue Policies | Inpatient Hospital Readmission | 00.01.47c | | 1/15/2017 | 8/7/2024 | | 8/7/2024 | | | |
| Reissue Policies | Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (APAP) and Bi-Level Devices | 05.00.30p | | 10/1/2023 | 8/21/2024 | | 8/21/2024 | | | |
| Reissue Policies | Spinal Cord Ganglion and Dorsal Root Ganglion Stimulation (AmeriHealth Administrators) | 11.15.01y | | 1/2/2024 | 8/21/2024 | | 8/21/2024 | | | |
| Reissue Policies | Pediatric Intensive Day Feeding Program | 10.00.03 | | 1/28/2019 | 8/21/2024 | | 8/21/2024 | | | |
| Reissue Policies | Percutaneous Vertebroplasty, Kyphoplasty, and Sacroplasty (AmeriHealth Administrators) | 11.14.10t | | 1/1/2023 | 8/21/2024 | | 8/21/2024 | | | |
| Reissue Policies | Palivizumab (Synagis) | 08.00.22q | | 9/25/2023 | 8/21/2024 | | 8/21/2024 | | | |
| Reissue Policies | Meniscal Allograft Transplantation and Meniscal Implants (AmeriHealth Administrators) | 11.14.03h | | 1/10/2021 | 8/21/2024 | | 8/22/2024 | | | |
| Reissue Policies | Sebelipase alfa (Kanuma®) | 08.01.28e | | 9/26/2022 | 8/21/2024 | | 8/26/2024 | | | |
| Reissue Policies | Therapeutic Shoes and Orthopedic Shoes | 05.00.11k | | 5/8/2023 | 8/21/2024 | | 8/27/2024 | | | |
| Reissue Policies | Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.) | 08.00.70e | | 6/3/2019 | 8/21/2024 | | 8/27/2024 | | | |
| Archived Policies | Electrical Bone Growth Stimulation and Low-Intensity Ultrasound Accelerated Fracture Healing System (Amerihealth Administrators) | 05.00.09i | 8/23/2024 11:00 AM | 9/23/2024 | | | 8/23/2024 | | | |
